TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers found that lower levels of the protective protein NRF2 in oligodendrocytes were associated with faster cognitive decline and abnormal myelin in human brain tissue. Experiments in mice suggest that reducing NRF2 in these cells can cause similar changes, but whether drugs targeting the pathway can slow age-related decline in people remains unknown.
Researchers have linked dysfunction in oligodendrocytes—brain cells that maintain the insulating coating around nerve fibers—to faster cognitive decline with age. In a study published in Nature Medicine, human brain tissue findings and experiments in mice connected lower levels of the protective protein NRF2 in these cells with abnormal myelin and loss of large nerve fibers, pointing to a possible treatment pathway that still needs testing in people.
The research, led by scientists from the University of Edinburgh and the UK Dementia Research Institute, drew on the Lothian Birth Cohort 1936. Participants had taken cognitive tests over many years. Of the 1,091 people enrolled, 866 completed additional testing after age 70, including assessments of memory, processing speed and spatial reasoning between ages 70 and 82. Most experienced some decline, but the pace differed between individuals.
Researchers examined brain tissue collected after death from a subset of participants. Those who had declined more over time tended to have fewer large nerve fibers and an abnormal buildup of myelin, the fatty coating that helps electrical signals travel along nerve fibers. These tissue differences were associated with the rate of cognitive change, rather than simply with a person’s test performance at one point in old age.
The team then investigated oligodendrocytes, which produce and maintain myelin. In people with greater decline, researchers found lower NRF2 levels in these cells. In mice, selectively reducing NRF2 in oligodendrocytes led to excess myelin, loss of large nerve fibers and less improvement on cognitive tests as the animals aged. The animal results support a possible causal role for NRF2 loss in the observed changes, but they do not establish that the same mechanism drives cognitive decline in humans.
A Potential Target in Aging Brains
The findings broaden the picture of age-related cognitive decline beyond damage to nerve cells themselves. They suggest that cells usually associated with protecting nerve fibers may also become dysfunctional, with consequences for myelin and communication between brain regions. That gives researchers a possible biological route to investigate when seeking ways to preserve thinking abilities in older age.
The study also points to NRF2 as a potential therapeutic target. The pathway is already targeted by medicines used for some neurological conditions, including multiple sclerosis. However, the research does not show that those drugs prevent or treat ordinary age-related cognitive decline. Any use for that purpose would require further studies of safety and benefit in older adults.
NRF2 supplement for cognitive health
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The Lothian Birth Cohort offers a long view of cognitive change because participants’ abilities were measured from childhood into old age. In this study, the researchers compared repeated test results with later findings from brain tissue, allowing them to examine whether biological features tracked with the pace of decline across adulthood.
Human tissue can reveal associations but cannot, by itself, establish what caused them. The mouse experiments were designed to test whether changing NRF2 in oligodendrocytes could produce similar abnormalities. The researchers reported that the changes in mice resembled those seen in human samples, providing experimental support for the proposed mechanism, while leaving open how closely the animal findings translate to people.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
Human Treatment Evidence Is Missing
The study does not establish that reduced NRF2 is the sole or primary cause of cognitive decline in people. The human findings are based on a subset of cohort participants whose brain tissue was available after death, and the reported associations cannot show on their own whether the cellular changes preceded or followed other processes linked to aging.
It is also not yet known whether increasing NRF2 activity would preserve cognition in older adults, which medicines might be suitable, or what benefits and risks treatment could carry. Evidence involving NRF2-targeting drugs in multiple sclerosis does not answer those questions for age-related cognitive decline.
Testing the Pathway in People
The next step is to establish whether the NRF2 pathway can be safely and meaningfully altered in ways that protect myelin and nerve fibers in aging brains. Further laboratory and animal work can clarify how oligodendrocyte dysfunction develops and whether it can be reversed. Researchers would then need clinical studies in older adults to test whether a medicine acting on the pathway changes cognitive outcomes.
Until such evidence is available, the findings identify a research direction, not a treatment recommendation. The study does not report a clinical trial of an NRF2-targeting drug for age-related cognitive decline, and it gives no timetable for one.
Key Questions
What are oligodendrocytes?
Oligodendrocytes are brain cells that produce and maintain myelin, the insulating layer around nerve fibers that helps electrical signals travel efficiently.
What did the study find in people?
In brain tissue from a subset of cohort participants, greater cognitive decline was associated with fewer large nerve fibers, abnormal myelin buildup and lower NRF2 levels in oligodendrocytes. The human findings show associations, not proof of cause.
Did the researchers test a treatment in people?
No. The reported work combined human brain tissue analysis with experiments in mice. It did not test an NRF2-targeting medicine as a treatment for age-related cognitive decline in people.
Could an existing multiple sclerosis drug help?
The research points to an NRF2-related pathway that is targeted by medicines used for other conditions, including multiple sclerosis. Whether such drugs could help older adults with cognitive decline remains unknown and would require clinical testing.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
